Vance Moore - Omnicell Independent Director

OMCL Stock  USD 29.23  0.01  0.03%   

Director

Mr. Vance B. Moore is an Independent Director of Omnicell Inc. Since February 2016, Mr. Moore has served as President, Business Integration of Mercy Health, a national healthcare system. From April 2011 to February 2016, Mr. Moore served as Senior Vice President, Operations of Mercy Health. From July 2006 to April 2011, Mr. Moore served as the President and Chief Executive Officer of Resource Optimization Innovation, the supply chain operating division of Mercy Health. From August 1998 to March 2007, Mr. Moore served in various capacities at ROi, including Chief Operating Officer. From March 1999 to March 2002, Mr. Moore served as the Vice President, Sales and Marketing of the Healthcare Services Division of UPS Logistics Group, a global supply chain management services company. Mr. Moore also serves as chairman of the board of ROi a director of Ascension Ventures, a strategic healthcare venture fund and a governing committee member of the Coordinating Center for the National Evaluation System for health Technology, a voluntary network of data partners focused on medical device performance since 2012.
Age 57
Tenure 12 years
Address 4220 North Freeway, Fort Worth, TX, United States, 76137
Phone877 415 9990
Webhttps://www.omnicell.com
Moore received a B.S. in industrial management from the University of Arkansas.

Omnicell Management Efficiency

Return On Capital Employed is expected to rise to -0.0099 this year. Return On Assets is expected to rise to -0.0087 this year. At this time, Omnicell's Intangible Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 297.7 M this year, although the value of Non Currrent Assets Other will most likely fall to about 52.5 M. Omnicell's management efficiency ratios could be used to measure how well Omnicell manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 614.09 M in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Omnicell has a current ratio of 2.07, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Omnicell until it has trouble settling it off, either with new capital or with free cash flow. So, Omnicell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Omnicell sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Omnicell to invest in growth at high rates of return. When we think about Omnicell's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Robert TretiakSo Young International
N/A
Michael LeavittHealthEquity
66
Lainie GoldsteinPhreesia
52
Francisco CaryPhreesia
49
Larry BinnionSo Young International
70
Adrian DillonHealthEquity
63
Hui ZhaoSo Young International
N/A
Kjersti KanneNational Research Corp
N/A
Rolando OliveiraPhreesia
N/A
Yang YuSo Young International
N/A
Bruce FeltEvolent Health
61
P ShastriNational Research Corp
65
Harald ArnetNational Research Corp
N/A
David FarnerEvolent Health
56
Savita AcharyaNational Research Corp
41
Matthew HobartEvolent Health
47
Benoit FloutierSo Young International
39
David HayesSo Young International
N/A
JoAnn MartinNational Research Corp
63
James BalasSo Young International
44
Rafael FunesPhreesia
50
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. Omnicell operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 4000 people. Omnicell (OMCL) is traded on NASDAQ Exchange in USA. It is located in 4220 North Freeway, Fort Worth, TX, United States, 76137 and employs 3,650 people. Omnicell is listed under Health Care Technology category by Fama And French industry classification.

Management Performance

Omnicell Leadership Team

Elected by the shareholders, the Omnicell's board of directors comprises two types of representatives: Omnicell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omnicell. The board's role is to monitor Omnicell's management team and ensure that shareholders' interests are well served. Omnicell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omnicell's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathleen Nemeth, Senior Relations
Sara Dalmasso, Senior International
Jorge Taborga, Executive Vice President - Engineering
Daniel Johnston, Chief Admin. Officer, Chief Legal Officer, Executive VP and Corporate Secretary
Minoo Mortazavi, Senior Operations
Joanne Bauer, Independent Director
Christopher Drew, Executive VP of Sales and Marketing
James Judson, Lead Independent Director
Bruce Smith, Director
Sara White, Independent Director
Nchacha Etta, Executive CFO
Randall Lipps, Executive Chairman, CEO and Pres
Scott Seidelmann, Executive Vice President and Chief Commercial Officer
Maximo Rocha, Senior Officer
Robin Seim, Executive VP for International and Global Quality and Manufacturing
Giri Chodavarapu, Senior Officer
Vance Moore, Independent Director
Joseph Spears, Principal Chief Accounting Officer
Mark Parrish, Independent Director
Vicki MacDevitt, Chief Staff
Randy Lindholm, Independent Director
Corey Manley, Executive Officer
Bruce Scott, Independent Director
David Vanella, Senior Regulatory
Roxanne Turner, Sr Officer
Gary Petersmeyer, Independent Director
Christine Mellon, Chief VP
Peter Kuipers, CFO, Executive Vice President
Brian Nutt, Chief VP
Nhat Ngo, Executive VP of Strategy and Bus. Devel.

Omnicell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omnicell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Omnicell is a strong investment it is important to analyze Omnicell's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Omnicell's future performance. For an informed investment choice regarding Omnicell Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.
Note that the Omnicell information on this page should be used as a complementary analysis to other Omnicell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Omnicell Stock analysis

When running Omnicell's price analysis, check to measure Omnicell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omnicell is operating at the current time. Most of Omnicell's value examination focuses on studying past and present price action to predict the probability of Omnicell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omnicell's price. Additionally, you may evaluate how the addition of Omnicell to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
CEOs Directory
Screen CEOs from public companies around the world
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is Omnicell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.68)
Earnings Share
(0.45)
Revenue Per Share
25.372
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.01)
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.